Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat
New drug in veterinary clinical practice - Oclacitinib maleate
dc.creator | Ćupić, Vitomir | |
dc.creator | Ivanović, Saša | |
dc.creator | Žugić, Gordana | |
dc.creator | Ćupić Miladinović, Dejana | |
dc.creator | Blagojević, Miloš | |
dc.date.accessioned | 2021-08-20T11:19:55Z | |
dc.date.available | 2021-08-20T11:19:55Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1840-2887 | |
dc.identifier.uri | https://vet-erinar.vet.bg.ac.rs/handle/123456789/2157 | |
dc.description.abstract | Uvođenjem novog leka oklacitinib maleata u veterinarsku kliničku praksu napravljen je značajan pomak u lečenju alergijskog i kliničkih slučajeva atopijskog dermatitisa (posebno pratećeg svraba) kod pasa. U lečenju ovih bolesti do sada su se najčešće koristili glukokortikoidi, ciklosporin i antihistaminici. Pokazalo se da ciklosporin ima sličnu aktivnost kao i glukokortikoidi, dok je aktivnost antihistaminika slabija. Novi lek oklacitinib maleat ima antiinflamatorni i antipruritični efekt sličan onom koji izazivaju glukokortikoidi i ciklosporin, ali mu (za razliku od njih) efekt brže nastupa, što mu daje veliku prednost. Oklacitinib je imunomodulator i ima specifičan mehanizam delovanja. Deluje tako što inhibira aktivnost enzima janus kinaza (pre svega JAK1 i JAK3), od kojih zavisi funkcija proinflamatornih i pruritogenih citokina. Oklacitinib je prilično bezbedan lek, ukoliko se koristi u kraćem vremenskom periodu i u preporučenim dozama. | sr |
dc.description.abstract | The introduction of a new drug oclacitinib maleate in veterinary clinical practice, has been made a big step forward in the treatment of allergic and clinical cases of atopic dermatitis (especially a accompanying pruritus) in dogs. So far glucocorticoids, cyclosporine, and antihistamines were most commonly used in the treatment of the above mentioned diseases. It has been shown that cyclosporine has a similar activity, as glucocorticosteroids, while the activity of antihistamines is weaker. New drug oclacitinib maleate has anti-inflammatory and antipruritic effect similar to that caused by glucocorticoids and cyclosporine, but (unlike them) it achieves more rapidly effect, which gives him a huge advantage. Oclacitinib is an immunomodulator and has a specific mechanism of action. It inhibits the activity of the Janus kinase enzymes (primarily JAK1 and JAK3), from which the function of pro-inflammatory and pruritic cytokines depends. Oclacitinib is a quite safe drug, if used in a shorter period of time, at the recommended doses. | sr |
dc.language.iso | sr | sr |
dc.publisher | Banja Luka : PI Veterinary Institute Republic of Srpska „Dr. Vaso Butozan“ | sr |
dc.rights | openAccess | sr |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Veterinarski žurnal Republike Srpske | sr |
dc.subject | oklacitinib maleat | sr |
dc.subject | alergijski i atopijski dermatitis | sr |
dc.subject | psi | sr |
dc.subject | oclacitinib maleate | sr |
dc.subject | allergic and atopic dermatitis | sr |
dc.subject | dogs | sr |
dc.title | Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat | sr |
dc.title | New drug in veterinary clinical practice - Oclacitinib maleate | sr |
dc.type | article | sr |
dc.rights.license | BY | sr |
dcterms.abstract | Ћупић-Миладиновић, Дејана; Ивановић, Саша; Благојевић, Милош; Жугић, Гордана; Ћупић, Витомир; Нови лек у ветеринарској клиничкој пракси - оклацитиниб малеат; Нови лек у ветеринарској клиничкој пракси - оклацитиниб малеат; | |
dc.citation.volume | 17 | |
dc.citation.issue | 1 | |
dc.citation.spage | 119 | |
dc.citation.epage | 128 | |
dc.identifier.doi | 10.7251/VETJ1701119I | |
dc.identifier.fulltext | https://vet-erinar.vet.bg.ac.rs/bitstream/id/5872/Novi_lek_u_pub_2017.pdf | |
dc.type.version | publishedVersion | sr |